Navigation Links
Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association

eutropenia. Eight percent of patients in the satraplatin arm experienced grade 3 or 4 gastrointestinal toxicities, including nausea (1.3%), vomiting (1.6%), diarrhea (2.1%) and constipation (2.1%). Five percent or less of patients in the satraplatin arm experienced grade 3 or 4 fatigue, grade 3 or 4 infections and pulmonary/respiratory grade 3 or 4 toxicities.

About Satraplatin

Satraplatin, an investigational drug, is a member of the platinum family of compounds. Platinum-based drugs are a critical part of modern chemotherapy treatments and are used to treat a wide variety of cancers. All platinum drugs currently on the market require intravenous administration. Satraplatin is an orally bioavailable compound and is given as capsules that patients can take at home.

A Phase 3 registrational trial, called SPARC, is evaluating satraplatin plus prednisone versus placebo plus prednisone in 950 patients with hormone-refractory prostate cancer whose prior chemotherapy has failed. Data from the trial on progression-free survival and on safety have been presented at recent medical conferences. In accordance with the recommendation of the independent Data Monitoring Board for the SPARC trial, patients who have not progressed continue to be treated and all patients will be followed for overall survival.

GPC Biotech has a co-development and license agreement with Pharmion GmbH, a wholly owned subsidiary of Pharmion Corporation, under which Pharmion has been granted exclusive commercialization rights to satraplatin for Europe and certain other territories. Pharmion has indicated it expects to complete the Marketing Authorization Application (MAA) for satraplatin for Europe in the second quarter of 2007. GPC Biotech in-licensed satraplatin from Spectrum Pharmaceuticals, Inc. in 2002.

Satraplatin has been studied in clinical trials involving a range of tumors. Trials evaluating the effects of satraplatin in combination with radiation therapy, in c
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:7/30/2015)... VALLEY COTTAGE, New York , July 30, 2015 ... the release of its latest report titled, "Continuous Glucose ... 2015 - 2020". According to the report, the global ... 402.0 Mn in 2014 and is expected to reach ... 12.1% during the forecast period, 2015 to 2020. ...
(Date:7/30/2015)... AUSTIN, Texas , July 30, 2015 ... solutions company focused on gynecologic disease, announced ... 2015 financial results after the market close ... an investor conference call and webcast at ... August 13, 2015 at 4:30pm Eastern/1:30pm Pacific  ...
(Date:7/30/2015)... July 30, 2015  NanoSmart Pharmaceuticals, Inc., a ... has received Orphan Drug Designation from the Food ... product that uses NanoSmart,s proprietary drug delivery platform. ... for the treatment of Ewing,s sarcoma, a rare ... NanoSmart,s Orphan Drug Designation on the basis of ...
Breaking Medicine Technology:Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
... the release dated August 24, 2011 with the following ... and should read: The Company will provide attendees an ... Form 8K with the SEC after the close of ...  This presentation will also be available at http://ir.questcor.com/sec.cfm ...
... DOYLESTOWN, Pa., Sept. 1, 2011 ProPhase Labs (NASDAQ: ... be donating $1,000 to a well-deserving, locally nominated and ... their "Share Your Cause, Not Your Cold" contest, hosted ... registered, qualified and valid non-for-profit organization organized under the ...
Cached Medicine Technology:UPDATING and ADDING: Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September 2UPDATING and ADDING: Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September 3Help Your Favorite Charity Win $1,000 from Cold-EEZE®! 2Help Your Favorite Charity Win $1,000 from Cold-EEZE®! 3
(Date:7/31/2015)... ... July 31, 2015 , ... Easter Seals Southern Georgia’s Heels & Wheels Duathlon & Triathlon will ... will be 7:30 AM. The duathlon is a 2 mile run, 13 mile bike ride, ... Lake, a 13 mile bike, and a 3 mile run. Heels & Wheels is ...
(Date:7/31/2015)... ... 2015 , ... Intellitec Solutions announced today they have expanded ... GP for a senior living facility in Maine. Having achieved recognition as a ... 16 states. This further expansion was again a factor of the firm’s success ...
(Date:7/31/2015)... TN (PRWEB) , ... July 31, 2015 , ... ... Tenn. has launched a Balloon Sinuplasty website to inform potential Nashville area ... a questionnaire that can be used to determine if someone is a good ...
(Date:7/30/2015)... ... July 31, 2015 , ... When responsible for the care ... out-of-reach. The questions race through your mind: What happens if mom falls? Who will ... overwhelmed and cancel your plans. , But not taking time away from caregiving responsibilities ...
(Date:7/30/2015)... Church, VA (PRWEB) , ... July 31, 2015 ... ... Manufacturing Floor:, Reduce Errors By 50% or More, **Presented by FDAnews and Ginette ... Dr. Ginette Collazo, a 15 year veteran of helping drug, biologic and device ...
Breaking Medicine News(10 mins):Health News:Heels & Wheels for Megan's House Set for Saturday August 22, 2015 in Waycross, Georgia 2Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 2Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 3Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4
... identified that a key protein called PEA-15 stops T-cell proliferation ... T-cell proliferation is essential in preventing certain blood cancers and ... response to infection. Findings of the study are reported ... , a publication of The Federation of American Societies for ...
... Boston with its famed medical institutions for a ... Combating Disease"? This historic Northeast city will, in fact, ... Chemical Society,s (ACS,) 240th National Meeting & Exposition, Aug. 22-26. ... print, broadcast, and online journalists a rich assortment of spot ...
... ... , ... May 4, 2010 -- Bold Software recently announced the second annual release of a ... technology. That study, combined with the company’s recent benchmarking analysis, shows that not ...
... the more cigarettes a woman smoked, the greater the ... woman who smokes while pregnant increases her baby,s risk ... a new Finnish study suggests. , While there,s plenty ... at risk for long-term health problems such as asthma, ...
... ... offers a potential boon to the diagnostic lab industry in the form of new business, ... lab industry expert Dennis Weissman at a Slone Partners teleconference on the new law April ... Miami, FL (PRWEB) ...
... ... partnership with Strategic Insight Publishing, took a step further with the release of ... Relationships. , ... 2010 -- Quoting verses from the book, the Founder and CEO of Myeexpert, Dr. Joel ...
Cached Medicine News:Health News:Study finds key protein controls T-cell proliferation 2Health News:Fear of Proactive Chat Unfounded According to Research by Bold Software 2Health News:Fear of Proactive Chat Unfounded According to Research by Bold Software 3Health News:Fear of Proactive Chat Unfounded According to Research by Bold Software 4Health News:Fear of Proactive Chat Unfounded According to Research by Bold Software 5Health News:Smoking While Pregnant May Raise Psychiatric Risks in Kids 2Health News:Smoking While Pregnant May Raise Psychiatric Risks in Kids 3Health News:Lab Industry Likely to Benefit from Expanded Preventive Testing Under New Health Care Law 2Health News:Lab Industry Likely to Benefit from Expanded Preventive Testing Under New Health Care Law 3Health News:“You Are Very Pretty”, Says Myeexpert As It Releases A Book, Poetic Expressions, Dedicated To The Beauty of Women. 2
... The Sysmex pocH-100i is the first ... with low daily testing requirements. With its ... 3-part differential from just 15 L of ... for any small healthcare site including the ...
... The Ichor hematology instrument is a ... When used with Plateletworks reagents, the Ichor ... standard CBC with platelet count plus platelet ... simple. A fresh whole blood sample is ...
... family, which includes the world's smallest ... most advanced pacemaker technology available, including ... first and only U.S. commercially approved ... (AF). The AF Suppression algorithm in ...
... CryoTherapy system uses catheters that are ... refrigeration console. The console processes the ... distal tip of the catheter, creates ... through an easy-to-use touch-screen interface. From ...
Medicine Products: